Lipum AB (publ)

Stockholm Stock Exchange LIPUM.ST

Lipum AB (publ) Total Assets for the year ending December 31, 2023

Lipum AB (publ) Total Assets is NA for the year ending December 31, 2023. Total assets are the total value of all assets owned by a company, representing its resources.

Key data

Date	Total Assets	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity

Stockholm Stock Exchange: LIPUM.ST

Lipum AB (publ)

CEO	Mr. Ola Sandborgh
IPO Date	April 22, 2021
Location	Sweden
Headquarters	Tvistevägen 48C
Employees	5
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of pediatric rheumatism and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116. The company was founded in 2010 and is headquartered in Umeå, Sweden.

Key trends

Past 5 years